Cetuximab is a therapeutic (monoclonal) antibody that binds specifically to the Epidermal Growth Factor Receptor (EGFR). By blocking the EGFR, Cetuximab interrupts the signalling pathway that stimulates tumor cell proliferation and survival[4].
Conventional Cetuximab production occurs in mammalian cell cultures. This process requires nutrient-rich growth media, which are often derived from animals. The production also requires energy-intensive bioreactors that provide precise environmental control. These media components are expensive and are often associated with a high environmental footprint due to their sourcing and processing[5].
We produce Cetuximab in the microalgae Chlamydomonas
reinhardtii,
which is grown using only light, carbon dioxide, and simple
nutrients.
This method reduces costs, energy and waste, and avoids the use of
animal-derived materials, making cancer therapy more affordable,
sustainable, and accessible.
(Read
more!)